Evidence map›Paper›PMID 35530961›Full record

ArticleAnnals of translational medicine2022

Effects of ginsenoside compound K on colitis-associated colorectal cancer and gut microbiota profiles in mice.

Li Shao, Yin-Ping Guo, Li Wang, Man-Yun Chen, Wei Zhang, Sheng Deng, Wei-Hua Huang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. The application ofAnnals of translational medicine · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Big lessons from the littleFrontiers in immunology · 2025
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Li ShaoDepartment of Pharmacognosy, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, China.
Yin-Ping GuoDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Li WangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Man-Yun ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Wei ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Sheng DengDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Wei-Hua HuangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNXiangya Hospital Central South University · CNHunan University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ginsenoside compound K (GC-K), generated from ginseng saponins bioconverted by gut microbiota, has potential anti-colorectal cancer (CRC) effects. Meanwhile, GC-K may interact with gut microbiota, playing important roles in the occurrence and development of CRC. However, the effects of gut microbiota on the preventive and therapeutic effects of GC-K in CRC remain to be elucidated. Methods: The anti-CRC effects of GC-K were evaluated in an azoxymethane/dextran sulfate sodium (AOM/DSS)-induced colitis-associated CRC Balb/c mice model under the dosage of 30 and 60 mg/kg. Stool samples were collected during the experiments for profiling gut microbiota by Results: GC-K could significantly suppress tumor growth Conclusions: GC-K was verified to suppress the tumor growth of AOM/DSS-induced colitis-associated CRC through the modulation of gut microbiota, partially by up-regulation of

Indexed as

16S rRNA gene sequencingAkkermansia muciniphila (A. muciniphila)colorectal cancer (CRC)Ginsenoside compound K (GC-K)gut microbiota

Identifiers

PMID35530961
PMCPMC9073768
OpenAlexW4229459903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.